Compare SLQT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | TENX |
|---|---|---|
| Founded | 1999 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 71.1M |
| IPO Year | 2020 | 2001 |
| Metric | SLQT | TENX |
|---|---|---|
| Price | $0.47 | $1.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.88 | ★ $29.67 |
| AVG Volume (30 Days) | 1.3M | ★ 5.1M |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,618,499,000.00 | N/A |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $0.48 | $1.31 |
| 52 Week High | $2.22 | $19.40 |
| Indicator | SLQT | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 26.47 |
| Support Level | $0.48 | $1.31 |
| Resistance Level | $0.79 | $2.22 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.00 | 0.43 |
| Stochastic Oscillator | 33.47 | 27.67 |
SelectQuote Inc is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. Its insurance distribution business allows consumers to transparently and conveniently shop for senior health, life, and automobile and home insurance policies from a curated panel of the nation's insurance carriers. It operates in three reportable segments: Senior, Healthcare Services, and Life. Senior sells senior Medicare-related health insurance products. Healthcare Services includes SelectRx, Healthcare Select, and SPM. Healthcare Services provides products and services to its Medicare policyholders, which are focused on improving patient health outcomes. Life sells term life and final expense products.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.